PROCEPT BioRobotics Corporation (PRCT) shareholders who lost Money have opportunity to lead securities fraud lawsuit. Sep 15, 2026, 13:20 ET LOS ANGELES, Sept. 15, 2026 /PRNewswire/ - Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against PROCEPT BioRobotics Corporation. IF YOU SUFFERED A LOSS ON YOUR PROCEPT BIOROBOTICS CORPORATION INVESTMENTS, CLICK HERE BEFORE SEPTEMBER 22, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About? The complaint filed in this class action alleges that between February 28, 2024 and February 25, 2026, Defendants made materially false and/or misleading statements regarding the Company's business, operations, and financial condition. Specifically, Defendants failed to disclose to investors that: (1) Procept used an extensive discount program designed to incentivize customers to place bulk handpiece orders in excess of procedure demand; (2) the undisclosed discount program artificially and unsustainably inflated Procept's reported U.S. handpiece unit sales and revenues by pulling forward sales at the expense of future periods; (3) the discount program caused customer handpiece orders to materially exceed underlying procedure demand throughout the Class Period, and this differential materially increased over time; (4) Procept's surplus of U.S. handpiece sales relative to procedures created excess field inventory and overstocking among its customers, totaling more than 10,000 excess units by the end of the Class Period; (5) as a result, Defendants materially overstated Procept's handpiece unit sales and the utilization of its field Systems; (6) Procept was exposed to undisclosed risks of significant operational and financial harm; and (7) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. What's The Next Step? Glancy Prongay Wolke & Rotter LLP is a leading national shareholder rights law firm, ready to assist you in potentially pursuing claims to recover your loss. If you wish to serve as lead plaintiff, you must move the Court no later September 22, 2026. Please contact us to learn more about your rights and interests by clicking here, by email ([email protected]), or by telephone at 310-201-9150 (Toll-Free: 888-773-9224). You may retain counsel of your choice. If you bought securities during the class period, you may take no action and remain an absent class member. No class has been certified yet. Why Glancy Prongay Wolke & Rotter LLP? GPWR is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Recognizing the firm's recent successes, GPWR was named one of Law360's Securities Groups of the Year and ranked 2nd in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025. GPWR's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. Prior results do not guarantee a similar outcome. Contact Us: Glancy Prongay Wolke & Rotter LLP, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 Charles Linehan Email: [email protected] Telephone: 310-201-9150 Toll-Free: 888-773-9224 Visit our website at: www.glancylaw.com. SOURCE Glancy Prongay Wolke & Rotter LLP

LAWSUIT INVESTOR NOTICE: Investors who lost money with Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares should contact the Shareholders Foundation. SAN DIEGO-(BUSINESS WIRE)-The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares in the U.S. District Court for Southern District of California (No: 3:26-cv-04385). Investors, who purchased a significant amount of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, in excess of $100,000 have certain options and there are short and strict deadlines running. Deadline: September 28, 2026. NASDAQ: CAPR investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. On July 30, 2026, an investor in NASDAQ: CAPR shares filed lawsuit over alleged securities laws violations by Capricor Therapeutics, Inc. The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that Capricor Therapeutics, Inc. adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for Deramiocel, that the FDA had not agreed to those changes before Capricor Therapeutics, Inc. resubmitted the Deramiocel Biologics License Application ("BLA"), that as a result, there was a significant risk that the FDA could conclude the clinical results did not provide substantial evidence of effectiveness of Deramiocel, and that as a result of the foregoing, there was a substantial risk to regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy. Those who purchased Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares should contact the Shareholders Foundation, Inc. The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon. Contacts. Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108 More News From The Shareholders Foundation, Inc. SAN DIEGO-( BUSINESS WIRE )-The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares in the U.S. District Court for the Northern District of California (No: 5:26-cv-07691). Investors, who purchased shares of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) have certain options. NASDAQ: PRCT investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. On... SAN DIEGO-( BUSINESS WIRE )-The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) shares in the U.S. District Court for the Southern District of California (No: 3:26-cv-04643). Investors, who purchased a significant amount of Aardvark Therapeutics, Inc. (NASDAQ: AARD) between February 13, 2025 and May 14, 2026, in excess of $100,000 have certain options and there are short and strict deadlines running. Deadline:... SAN DIEGO-( BUSINESS WIRE )-The Shareholders Foundation, Inc. announced an update in the lawsuit that is pending for certain investors in Adobe Inc. (NASDAQ: ADBE) shares in the U.S. District Court for the Southern District of New York (No: 23-CV-09260).Investors who purchased shares of Adobe Inc. prior to June 2021 and continue to hold any of those NASDAQ: ADBE shares have also certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779-... The Shareholders Foundation, Inc. NASDAQ:CAPR Release Versions Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108

PROCEPT faces legal storm over sales practices missteps. Investors take aim: A legal showdown on the horizon. There's a brewing storm over at PROCEPT BioRobotics - ticker NASDAQ:PRCT if you're tracking. These folks are knee-deep in a securities class action lawsuit from investors who've taken a financial wallop. The lawsuits are triggered by allegations of shady sales techniques that artificially bumped up their unit sales numbers, leaving some shareholders with substantial losses. From February 2024 to February 2026, investors unknowingly danced to the company's tune. However, as time wore on, those tunes turned out to be offbeat, revealing an orchestra of unsustainable sales maneuvers that included late sales pushes and bulk discounts that piled up inventories way higher than actual demand. Let that sink in - 10,000 excess units gathering dust while they fed off tomorrow's customer orders to pretty up today's books. Shades of misconduct: behind the padded sales numbers. Now, let's tear into what was happening under PROCEPT's hood. It's alleged that their "growth story" wasn't exactly telling the whole truth. Imagine stacking unit sales high through enticing bulk discounts, daring customers to fill their shelves with goods they didn't need. All this made those quarterly numbers look peachy-keen, until the truth slyly slipstreamed into their financial results. This rampant inventory padding came to light with slashed sales predictions, first in August 2025 and again when they couldn't shake their numbers back into line by November. Each belly flop in forecast pointed to something stinking in the numbers game. By February 2026, the cold, hard truth punched through when PROCEPT finally fessed up to the inventory bloat. Stock price vs. Reality: A lesson in transparency. Here's the kicker: this inventory circus had a real price tag for PROCEPT's investors. The stock nosedived by $22.06, which, if you're counting, is a hefty 48% drop from its August 2025 stature. Investors learned the hard way that what's shiny on paper might just peel off in reality. Reed Kathrein from Hagens Berman didn't mince words: "We're focused on whether PROCEPT may have intentionally pulled-in sales from future quarters to make it seem like the company was meeting expectations and, if so, whether the company had been sufficiently transparent in its investor communications." It's a classic case of transparency - or lack thereof - coming home to roost. Did PROCEPT play a slick game of smoke and mirrors to dodge Wall Street's ire? That's the $64,000 question, and it's got the legal eagles sharpening their talons. * Surprise underperformance in core product sales. * Accusations of hiding the real financial picture. * Massive decline in stock value, impacting investor trust. Roll up your sleeves, investors: navigating the implications. For all the investors caught in the headlights, there's a glimmer of opportunity. The lawsuit, steered by Hagens Berman Sobol Shapiro LLP, offers an avenue to potentially recuperate some of those hefty losses. The firm is rallying others to join their cause, motivated by the chronicles of bulk discounts and manipulated sales performance that turned into a high-stakes gamble. So, what's the play for anyone in the trenches with PROCEPT stock? Keep those ears to the ground and eyes peeled on the legal process. The allegations are stacked higher than a jittery trader's caffeine intake, and how this navigates through the courts could set precedent, or at least a learning moment for others crafting their fiscal narrative. In a sector where innovation mingles with uncertainty, investors must weigh every disclosed metric as though it might carry a double meaning. Maybe it's about time investors demand robust reporting that captures not just the gloss, but the grit. Navigating this legal quagmire won't be quick or easy, but for folks with losses or those holding the key to more insights, it's a silver lining when you get to call out corporate missteps and get ahead with potential recoveries.